Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine

Current Opinion in Pharmacology

Volumn 8, Issue 4, 2008, Pages 359-362

  Workman, Paul ^a   de Bono, Johann ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; B RAF KINASE; BCR ABL PROTEIN; CYTOCHROME P450 17; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; K RAS PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESEARCH; CANCER RESISTANCE; CELL SURVIVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SENSITIVITY; DRUG TARGETING; EDITORIAL; GASTROINTESTINAL TUMOR; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; ONCOGENE PROTEINS V-ABL; ONCOGENES; RECEPTOR, ERBB-2;

EID: 51449103841     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.07.007     Document Type: Editorial

References (24)

1. In: Bronchud M.H., Foote M.A., Giaccone G., Olopade O., and Workman P. (Eds). Principles of Molecular Oncology. edn 3 (2008), Human Press, Totowa, New Jersey
2. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
3. http://www.sanger.ac.uk/genetics/CGP/. A valuable resource within which to search for mutations present in human cancers.
4. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
5. Wood L.D., Parsons D.W., Jones S., Lin J., Sjöblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
6. Collins I., and Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2 (2006) 689-700
7. Land H., Parada L.F., and Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304 (1983) 596-602
8. Ruley H.E. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 304 (1983) 602-606
9. McMurray H.R., Sampson E.R., Compitello G., Kinsey C., Newman L., Smith B., Chen S.R., Klebanov L., Salzman P., Yakovlev A., and Land H. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature 453 (2008) 1112-1116. Identifies genes involved in the oncogenic co-operation between p53 and RAS and shows that silencing of several examples of these genes inhibits tumour growth - suggesting new potential targets for therapy.
10. Weinstein I.B. Addiction to oncogenes - the Achilles heal of cancer. Science 297 (2002) 63-64
11. Weinstein I.B., and Joe A. Oncogene addiction. Cancer Res 68 (2008) 3077-3080. A useful update on the concept of oncogene addiction.
12. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-546
13. Benson J.D., Chen Y.N., Cornell-Kennon S.A., Dorsch M., Kim S., Leszczyniecka M., Sellers W.R., and Lengauer C. Validating cancer drug targets. Nature 441 (2006) 451-456
14. Kaelin Jr. W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5 (2005) 689-698
15. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362. This work shows that cell lines with mutant BRAF are hypersensitive to the inhibition of MEK, when compared to either wild-type cells or cells harbouring a RAS mutation - providing another clinically relevant example of oncogene addiction.
16. Raynaud F.I., Eccles S., Clarke P.A., Hayes A., Nutley B., Alix S., Henley A., Di-Stefano F., Ahmad Z., Guillard S., et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67 (2007) 5840-5850. This work provides detailed characterisation of the pharmacological and therapeutic activity of a class I PI3 kinase inhibitor and illustrates the potential of this approach.
17. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921. Together with Ref. [18••], this work demonstrates that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitises cells to the inhibition of PARP, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis - thus providing proof of concept for clinically exploitable synthetic lethality.
18. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., and Helleday T. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917. See annotation to Ref. [17••].
19. Silva J.M., Marran K., Parker J.S., Silva J., Golding M., Schlabach M.R., Elledge S.J., Hannon G.J., and Chang K. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319 (2008) 617-620. Together with Ref. [20••], this work demonstrates the use of high-throughput RNA interference screening to identify non-oncogenes that are preferentially required by cancer versus normal cells - suggesting a range of new targets for therapeutic intervention.
20. Schlabach M.R., Luo J., Solimini N.L., Hu G., Xu Q., Li M.Z., Zhao Z., Smogorzewska A., Sowa M.E., Ang X.L., et al. Cancer proliferation gene discovery through functional genomics. Science 319 (2008) 620-624. See annotation to Ref. [19••].
21. Workman P. Drugging the cancer genome: new challenges of infrequent and combinatorial targets. Curr Opin Invest Drugs 8 (2007) 445-446. This commentary provides a perspective on the discovery (see Refs. [4,5]) that individual human cancers contain surprisingly large numbers of 'driver' mutations and that many cancer genes are mutated relatively rarely overall - also emphasises the need for combinatorial therapies and the importance of a systems approach to understand and treat cancer.
22. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., Inserra E., Diederichs S., Iafrate A.J., Bell D.W., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) [EPub ahead of print]. This study emphasizes the potential of circulating tumour cells to provide an easily accessible means to perform molecular analysis and determine response to drugs.
23. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
24. Workman P., Aboagye E.O., Chung Y.L., Griffiths J.R., Hart R., Leach M.O., Maxwell R.J., McSheehy P.M., Price P.M., Zweit J., and Cancer Research UK Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98 (2006) 580-598. This is a review, based on UK experience, focussing on the use of molecular and functional imaging methods in the context of early clinical trials - together with recommendations for the future.